Leptin for type 1 diabetes: Coming onto stage to be (or not?)

Pediatric Diabetes

Volumn 13, Issue 1, 2012, Pages 68-73

  Oral, Elif A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Autoimmunity; Glucagon; Insulin; Lipotoxicity; Therapeutics

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN RECEPTOR; LEPTIN; LIPID; PRAMLINTIDE; RECOMBINANT LEPTIN; STREPTOZOCIN;

ADIPOSE TISSUE; APPETITE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE LIPODYSTROPHY; CLINICAL FEATURE; CLINICAL RESEARCH; DIABETIC PATIENT; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATTY LIVER; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEPATOMEGALY; HOMEOSTASIS; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERGLUCAGONEMIA; IN VIVO STUDY; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LEPTIN DEFICIENCY; LIPID METABOLISM; LIPODYSTROPHY; LIPOGENESIS; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; PANCREAS ISLET CELL; PATIENT SATISFACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STEATOSIS; STREPTOZOCIN DIABETES; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOCYTES; ANIMALS; DIABETES MELLITUS, TYPE 1; ENERGY METABOLISM; HUMANS; LEPTIN; LIPID METABOLISM; LIPODYSTROPHY; MUTATION; OBESITY; RECEPTOR, INSULIN;

EID: 84856401980     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2011.00797.x     Document Type: Article

References (20)

1. Wang MY, Chen L, Clark GO et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A 2010: 107: 4813-4819.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994: 372: 425-432.
3. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998: 395: 763-770.
4. Begriche K, Letteron P, Abbey-Toby A et al. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 2008: 294: E939-E951.
5. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999: 401: 73-76.
6. Cohen P, Miyazaki M, Socci ND et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002: 297: 240-243.
7. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003: 24: 78-90.
8. Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002: 415: 339-343.
9. Asilmaz E, Cohen P, Miyazaki M et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 2004: 113: 414-424.
10. Cohen P, Zhao C, Cai X et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 2001: 108: 1113-1121.
11. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011: 60: 391-397.
12. Hancock AS, Du A, Liu J, Miller M, May CL. Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 2010: 24: 1605-1614.
13. Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004: 351: 987-997.
14. Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002: 346: 570-578.
15. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002: 110: 1093-1103.
16. Ravussin E, Smith SR, Mitchell JA et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009: 17: 1736-1743.
17. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003: 65: 333-347.
18. Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract 2010: 16: 324-333.
19. Park JY, Chong AY, Cochran EK et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab 2008: 93: 26-31.
20. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 2004: 89: 1548-1554.